Scott Spector, MD
Ophthalmology · Norwalk, CTNPI 1073553707
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 28.2% of the total. Reporting peaked in 2019 at $9,417 and has fallen 64.2% since, to $3,366 in 2025. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 410 payments — averaging $56.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$7K
- Johnson & Johnson Surgical Vision, Inc.$4K
- AbbVie$2K
- Eyevance Pharmaceuticals LLC$2K
- Harrow Eye, LLC$1K
- Alcon$1K
- plus $6K from 29 others
What the payments were for
- Consulting fees$5,78225%
- Speaking & faculty fees$2,50011%
- Grants$790%
- Travel & lodging$1,5967%
- Food & beverage$13,32457%
- Gifts$450%
- Entertainment$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$3,370
- INVELTYS$2,746
- Tecnis 1-piece IOL$1,832
- Tecnis 3-piece IOL$1,832
- Tecnis Symphony IOL$1,832
- Tecnis Symphony Toric IOL$1,832
- Tecnis Symfony IOL$1,532
- Flarex$1,233
- CEQUA$374
- LUMIGAN$365
- RXSIGHT CONTACT LENS$297
- RXSIGHT INJECTOR CARTRIDGE$297
- RXSIGHT INJECTOR HANDPIECE$297
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$297
- Zerviate$269
- TRYPTYR$261
- OMIDRIA$250
- DEXYCU$232
- MIEBO$229
- XIIDRA$229
How this compares
$23,347 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 62 | $88,448 |
| LumiganBimatoprost | 54 | $35,017 |
| XiidraLifitegrast | 14 | $16,019 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 67 | $15,004 |
| Cyclosporine | 25 | $12,168 |
| Loteprednol Etabonate | 59 | $9,457 |
| IlevroNepafenac | 25 | $9,430 |
| Tobradex StTobramycin/Dexamethasone | 36 | $8,819 |
| ProlensaBromfenac Sodium | 24 | $8,759 |
| Bromfenac Sodium | 63 | $8,686 |
| Lotemax SmLoteprednol Etabonate | 27 | $8,349 |
| Prednisolone Acetate | 218 | $8,174 |
| VyzultaLatanoprostene Bunod | 20 | $7,214 |
| Fluorometholone | 89 | $7,138 |
| EysuvisLoteprednol Etabonate | 13 | $6,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $2,038 | $126,264129 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm | $632 | $26,564110 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $622 | $23,23334 claims |
| AlconSimbrinza | $1,306 | $15,00467 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $1,887 | $11,51257 claims |
| NovartisIlevro | $249 | $9,43025 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $6,573 | $6,47313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Norwalk
- Erol VerterNorwalk$5K
- Ding MaNorwalk$5K
- Jay FleischmanNorwalk$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.